Welcure Drugs [WELCURE] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Welcure Drugs

BSE
Loading...

Divi's Laboratories

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Welcure Drugs wins in 7 metrics, Divi's Laboratories wins in 12 metrics, with 0 ties. Divi's Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricWelcure DrugsDivi's LaboratoriesBetter
P/E Ratio (TTM)2.2467.57Welcure Drugs
Price-to-Book Ratio0.4510.40Welcure Drugs
Debt-to-Equity Ratio120.180.03Divi's Laboratories
PEG Ratio0.002.55Welcure Drugs
EV/EBITDA5.5749.66Welcure Drugs
Profit Margin (TTM)7.96%23.89%Divi's Laboratories
Operating Margin (TTM)10.38%25.60%Divi's Laboratories
EBITDA Margin (TTM)10.38%25.60%Divi's Laboratories
Return on Equity2.12%14.64%Divi's Laboratories
Return on Assets (TTM)0.81%12.94%Divi's Laboratories
Free Cash Flow (TTM)$-2.22B$2.15BDivi's Laboratories
Dividend YieldN/A0.91%N/A
1-Year Return-13.65%-0.61%Divi's Laboratories
Price-to-Sales Ratio (TTM)0.2116.13Welcure Drugs
Enterprise Value$1.91B$1,522.01BDivi's Laboratories
EV/Revenue Ratio0.5915.77Welcure Drugs
Gross Profit Margin (TTM)10.40%60.33%Divi's Laboratories
Revenue per Share (TTM)$38$363Divi's Laboratories
Earnings per Share (Diluted)$2.69$86.82Divi's Laboratories
Beta (Stock Volatility)-2.070.18Welcure Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Welcure Drugs vs Divi's Laboratories Stock Performance Analysis

Loading Price Chart...

Welcure Drugs
Divi's Laboratories
Welcure Drugs Stock Overview | Divi's Laboratories Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Welcure Drugs4.97%20.73%-33.73%-43.59%-19.42%-40.13%
Divi's Laboratories0.26%7.29%1.28%-11.38%16.08%0.52%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Welcure Drugs-13.65%-18.73%225.49%196.43%109.46%-49.31%
Divi's Laboratories-0.61%70.86%89.42%470.70%1,608.03%8,411.57%

News Based Sentiment: Welcure Drugs vs Divi's Laboratories

Welcure Drugs

News based Sentiment: MIXED

October was a pivotal month for Welcure Drugs, marked by a potential acquisition offer and significant financial growth, but also continued stock volatility and regulatory scrutiny. The mixed signals create a complex investment picture, making it a significant month for the company's trajectory.

View Welcure Drugs News Sentiment Analysis

Divi's Laboratories

News based Sentiment: MIXED

Divi's Laboratories reported strong quarterly results and is strategically diversifying its revenue base, but faces operational challenges and mixed analyst sentiment. The technical indicators also present a cautious outlook, creating a complex investment narrative with both opportunities and risks.

View Divi's Laboratories News Sentiment Analysis

Performance & Financial Health Analysis: Welcure Drugs vs Divi's Laboratories

MetricWELCUREDIVISLAB
Market Information
Market Cap i₹712.18M₹1.61T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i8,204,994455,187
90 Day Avg. Volume i6,251,926395,686
Last Close₹6.97₹6,120.50
52 Week Range₹5.26 - ₹15.89₹4,955.00 - ₹7,071.50
% from 52W High-56.14%-13.45%
All-Time High₹25.00 (Sep 19, 2005)₹7,071.50 (Jul 08, 2025)
% from All-Time High-72.12%-13.45%
Growth Metrics
Quarterly Revenue Growth-34.93%0.14%
Quarterly Earnings GrowthN/A0.27%
Financial Health
Profit Margin (TTM) i0.08%0.24%
Operating Margin (TTM) i0.10%0.26%
Return on Equity (TTM) i0.02%0.15%
Debt to Equity (MRQ) i120.180.03
Cash & Liquidity
Book Value per Share (MRQ)₹13.32₹563.87
Cash per Share (MRQ)₹0.01₹132.86
Operating Cash Flow (TTM) i₹-2,249,340,000₹19.67B
Levered Free Cash Flow (TTM) i₹21.70M₹21.91B
Dividends
Last 12-Month Dividend Yield iN/A0.91%
Last 12-Month Dividend iN/A₹60.00

Valuation & Enterprise Metrics Analysis: Welcure Drugs vs Divi's Laboratories

MetricWELCUREDIVISLAB
Price Ratios
P/E Ratio (TTM) i2.2467.57
Forward P/E iN/A104.19
PEG Ratio i0.002.55
Price to Sales (TTM) i0.2116.13
Price to Book (MRQ) i0.4510.40
Market Capitalization
Market Capitalization i₹712.18M₹1.61T
Enterprise Value i₹1.91B₹1.52T
Enterprise Value Metrics
Enterprise to Revenue i0.5915.77
Enterprise to EBITDA i5.5749.66
Risk & Other Metrics
Beta i-2.070.18
Book Value per Share (MRQ) i₹13.32₹563.87

Financial Statements Comparison: Welcure Drugs vs Divi's Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)WELCUREDIVISLAB
Revenue/Sales i₹3.00B₹24.10B
Cost of Goods Sold i₹2.69B₹9.56B
Gross Profit i₹311.96M₹14.54B
Research & Development iN/AN/A
Operating Income (EBIT) i₹311.36M₹6.17B
EBITDA i₹311.41M₹8.48B
Pre-Tax Income i₹311.36M₹7.33B
Income Tax i₹78.37M₹1.88B
Net Income (Profit) i₹232.99M₹5.45B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)WELCUREDIVISLAB
Cash & Equivalents i₹1.28M₹4.15B
Total Current Assets i₹1.82B₹100.81B
Total Current Liabilities i₹412.69M₹14.52B
Long-Term Debt i₹1.23B₹20.00M
Total Shareholders Equity i₹1.03B₹149.69B
Retained Earnings i₹-100.79M₹134.00B
Property, Plant & Equipment iN/A₹3.19B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)WELCUREDIVISLAB
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricWELCUREDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i8,204,994455,187
Average Daily Volume (90 Day) i6,251,926395,686
Shares Outstanding i112.51M265.47M
Float Shares i14.84M120.77M
% Held by Insiders i0.85%0.52%
% Held by Institutions i0.00%0.29%

Dividend Analysis & Yield Comparison: Welcure Drugs vs Divi's Laboratories

MetricWELCUREDIVISLAB
Last 12-Month Dividend iN/A₹60.00
Last 12-Month Dividend Yield iN/A0.91%
3-Year Avg Annual Dividend iN/A₹50.00
3-Year Avg Dividend Yield iN/A0.70%
3-Year Total Dividends iN/A₹150.00
Ex-Dividend DateN/AJul 25, 2025